Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

ACRS

Aclaris Therapeutics (ACRS)

Aclaris Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ACRS
DateTimeSourceHeadlineSymbolCompany
23/11/202408:00Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ACRSAclaris Therapeutics Inc
22/11/202408:51Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ACRSAclaris Therapeutics Inc
21/11/202408:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
20/11/202408:05AllPennyStocks.comThis Healthcare Stock Soared Following Exclusive License Agreement AnnouncementNASDAQ:ACRSAclaris Therapeutics Inc
19/11/202408:20Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
19/11/202400:50PR Newswire (US)Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology AssetsNASDAQ:ACRSAclaris Therapeutics Inc
19/11/202400:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRSAclaris Therapeutics Inc
19/11/202400:10GlobeNewswire Inc.Aclaris Therapeutics Announces $80 Million Private PlacementNASDAQ:ACRSAclaris Therapeutics Inc
19/11/202400:10GlobeNewswire Inc.Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to PipelineNASDAQ:ACRSAclaris Therapeutics Inc
07/11/202408:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACRSAclaris Therapeutics Inc
06/11/202423:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRSAclaris Therapeutics Inc
06/11/202423:00GlobeNewswire Inc.Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
06/11/202408:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
04/10/202406:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
17/09/202421:00GlobeNewswire Inc.Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic DermatitisNASDAQ:ACRSAclaris Therapeutics Inc
10/09/202421:00GlobeNewswire Inc.Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare ConferenceNASDAQ:ACRSAclaris Therapeutics Inc
05/09/202409:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
05/09/202407:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
14/08/202406:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
07/08/202421:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRSAclaris Therapeutics Inc
07/08/202421:00GlobeNewswire Inc.Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
06/08/202406:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
17/07/202406:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRSAclaris Therapeutics Inc
17/07/202406:01GlobeNewswire Inc.Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 MillionNASDAQ:ACRSAclaris Therapeutics Inc
11/06/202406:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
11/06/202406:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
11/06/202406:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
08/06/202406:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRSAclaris Therapeutics Inc
06/06/202421:00GlobeNewswire Inc.Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:ACRSAclaris Therapeutics Inc
05/06/202406:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ACRS